Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors

Tumori

Volumn 92, Issue 6, 2006, Pages 531-535

  Ferrari, Leonardo ^a   Della Torre, Silvia ^b   Collini, Paola ^a   Martinetti, Antonia ^a   Procopio, Giuseppe ^a   De Dosso, Sara ^a   Bajetta, Roberto ^a   Catena, Laura ^a   Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ITMO   (Italy)

Author keywords

CD117; Ki 67; Kit protein; Neuroendocrine tumors; Proliferation index

Indexed keywords

IMATINIB; KI 67 ANTIGEN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; DRUG RESEARCH; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MYELOID LEUKEMIA; NEUROENDOCRINE TUMOR; PROTEIN EXPRESSION; TUMOR CLASSIFICATION;

EID: 33846477327     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200611     Document Type: Article

References (22)

1. Huang SM, Harari PM: Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary results. Invest New Drugs, 17: 259-269, 1999.
2. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jonnes S, Druker BJ, Lydon NB: Abl protein kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther, 295: 139-145, 2000.
3. Demetri GD: Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol, 28 (suppl 17): 19-26, 2001.
4. Druker BJ: STI571 (Gleevec) as paradigm for cancer therapy. Trends Mol Med, 8 (suppl 4): S14-S18, 2002.
5. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H, Kitamura Y: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumours. Cancer Res, 59: 4297-4300, 1999.
6. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford MJ, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344: 1031-1037, 2001.
7. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med, 344: 1052-1056, 2001.
8. Sawyers CL, Druker B: Tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J Sci Am, 5: 63-69, 1999.
9. Bajetta E, Procopio G, Ferrari L, Catena L, Del Vecchio M, Bombardieri E: Update on the treatment of neuroendocrine tumors. Expert Rev Anticancer Ther, 3: 631-642, 2003.
10. Solcia E, Klöppel G, Sobin LH: Histological typing of endocrine tumours, 2nd ed, Springer Verlag, Berlin, Heidelberg, New York, Barcelona, Hong Kong, London, Milan, Paris, Singapore, Tokyo, 2000.
11. Araki K, Ishii G, Yokose T, Nagai K, Funai K, Kodama K, Nishiwaki Y, Ochiai A: Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer, 40: 173-180, 2003.
12. Fjällskog ML, Lejonklou MH, Öberg KE, Eriksson BK, Janson ET: Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res, 9: 1469-1473, 2003.
13. Sampietro G, Tomasic G, Collini P, Biganzoli E, Boracchi P, Bidoli P, Pilotti S: Gene product immunophenotyping of neuroendocrine tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis. Appl Immunohistochem Mol Morphol, 8: 49-56, 2000.
14. Sabah M, Leader M, Kay E: The problem with c-kit: clinical implications and practical difficulties with CD117 immunostaining. Appl Immunohistochem Mol Morphol, 11: 56-61, 2003.
15. Butnor KJ, Burchette JL, Sporn TA, Hammar SP, Roggli VL: The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors. A study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med, 128: 538-543, 2004.
16. Kostula V, Kan K, Savage K, Stubbs M, Quaglia A, Dhillon AP, Hochhauser D, Caplin ME: Expression of c-kit (CD117) in neuroendocrine tumors - A target for therapy? Oncol Rep, 13: 643-647, 2005.
17. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC: Tumors of the lung, pleura, thymus and heart. IARC Press, Lyon, 2004.
18. Su LD, Fullen DR, Lowe L, Uherova P, Schnitzer B, Valdez R: CD117 (Kit receptor) expression in Merkel cell carcinoma. Am J Dermatopathol, 24: 289-293, 2002.
19. Reyes A, Moran CA, Suster S, Michal M, Dominguez H: Neuroendocrine carcinomas (carcinoid tumor) of the testis. A clinicopathologic and immunohistochemical study of ten cases. Am J Clin Pathol, 120: 182-187, 2003.
20. Johnson BE, Fischer T, Fischer D, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornik J, Salgia R, Le Chevalier T: Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res, 9: 5825-5828, 2003.
21. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, Takagi H, Takahashi T: Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene, 6: 2291-2296, 1991.
22. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettnen M: Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumours and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol, 154: 53-60, 1999.